Title : Optimising MS disease-modifying therapies: antibodies in perspective.

Pub. Date : 2004 Sep

PMID : 15549353

6 Functional Relationships(s)
Compound Name
Protein Name
1 A proportion of people with multiple sclerosis (MS) treated with interferon (IFN) a develop neutralising anti-IFN beta antibodies (NABs). nabs interferon beta 1 Homo sapiens
2 In patients treated with IFN beta in whom NABs persist for a significant period of time, their presence is associated with a reduction in both the biological effects and clinical efficacy. nabs interferon beta 1 Homo sapiens
3 The persistence of NABs appears to be linked to the type of IFN beta treatment as well as the titre of antibodies. nabs interferon beta 1 Homo sapiens
4 The overall efficacy of IFN beta and, hence, of any biological disease-modifying treatment (DMT) would be substantially improved if the development of NABs could be prevented or reversed. nabs interferon beta 1 Homo sapiens
5 As a corollary, the therapeutic efficacy of IFN beta could be maximised if patients who tolerate higher-dose preparations could be prevented from developing persistent NABs. nabs interferon beta 1 Homo sapiens
6 Strategies employed to prevent or reverse the development of NABs with other biological compounds (e. g. insulin, factor VIII, IFN beta, recombinant human erythropoietin) include improvements in the manufacturing process, immunosuppression, induction of tolerance and deimmunisation, and these should be considered in relation to biological DMT therapy as part of future clinical studies. nabs interferon beta 1 Homo sapiens